Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

Lingzhi Hong, Marcelo V. Negrao, Seyedeh S. Dibaj, Runzhe Chen, Alexandre Reuben, Jadi M. Bohac, Xiaoke Liu, Ferdinandos Skoulidis, Carl M. Gay, Tina Cascone, Kyle G. Mitchell, Hai T. Tran, Xiuning Le, Lauren A. Byers, Boris Sepesi, Mehmet Altan, Yasir Y. Elamin, Frank V. Fossella, Jonathan M. Kurie, Charles LuFrank E. Mott, Anne S. Tsao, Waree Rinsurongkawong, Jeff Lewis, Don L. Gibbons, Bonnie S. Glisson, George R. Blumenschein, Emily B. Roarty, P. Andrew Futreal, Ignacio I. Wistuba, Jack A. Roth, Stephen G. Swisher, Vassiliki A. Papadimitrakopoulou, John V. Heymach, J. Jack Lee, George R. Simon, Jianjun Zhang

Research output: Contribution to journal › Article › peer-review

104 Scopus citations

Fingerprint

Dive into the research topics of 'Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC'. Together they form a unique fingerprint.

Medicine & Life Sciences